Bendeka Injection, Solution
Product Images NDC 63459-348

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bendeka (NDC 63459-348). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Bendeka 01)

Chemical structure of bendamustine hydrochloride, the active ingredient in Bendeka injection solution. The diagram shows the molecular arrangement including chlorinated alkyl groups, a pyrimidine ring, and a methylated nitrogen with a carboxylic acid hydrochloride component.*

FDA Label Image

Figure 1 (Bendeka 02)

A survival distribution function plot showing survival probabilities over time. The y-axis represents survival distribution function values from 0 to 1, and the x-axis represents time units approximately from 0 to 45. The plot includes two distinct stepped lines indicating survival trends for two different groups or conditions.*

FDA Label Image

Carton Label (Bendeka 03)

Packaging label for Bendeka 100 mg/4 mL (25 mg/mL) injection containing bendamustine hydrochloride, indicated for intravenous infusion. The label displays the product name, strength, dosage form, and labeling as a sterile multi-dose vial. It includes storage instructions, distributor information (Teva Pharmaceuticals USA, Inc.), and a caution about cytotoxic handling. The label features barcodes and the Teva logo.*

FDA Label Image

Vial Label (Bendeka 04)

Label for Bendeka (bendamustine hydrochloride) Injection, 100 mg/4 mL (25 mg/mL) concentrate solution for intravenous infusion. The label notes that the solution must be diluted prior to administration, provides storage instructions to keep refrigerated at 2° to 8°C, and includes warnings about proper handling and dilution. The product is distributed by Teva Pharmaceuticals USA, Inc. and is labeled as Rx only.*

FDA Label Image

Alternate Carton Label (Bendeka 05)

Packaging label for Bendeka (bendamustine HCl) Injection, 100 mg/4 mL (25 mg/mL) intravenous solution. The label indicates it is a cytotoxic agent, sterile, for intravenous infusion only, and must be diluted prior to administration. Distributed by Teva Pharmaceuticals USA, Inc. The label includes storage instructions and highlights this is a multi-dose vial with NDC 63459-348-04.*

FDA Label Image

Alternate Vial Label (Bendeka 06)

Label for Bendeka (bendamustine hydrochloride) Injection, 100 mg/4 mL (25 mg/mL) solution for intravenous infusion. This multi-dose vial label includes storage instructions to keep refrigerated at 2° to 8°C, a caution that the solution must be diluted prior to administration, and mentions the labeler Teva Pharmaceuticals USA, Inc., Parsippany, NJ, with product origin Italy. The label references package insert for dosing and dilution guidance and indicates the product NDC 63459-348-04.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.